488 OriA631-B: a first-in class CD39/PD-L1 bispecific antibody unleashing enhanced cancer immunotherapy

• Yuchen Zhang,
• Huajing Wang,
• Xian-Yang Li,
• Xiaowen He,
• Xiaopei Li,
• Qi Deng

Affiliations

Yuchen Zhang

2Xi’an Jiaotong University, Shaanxi, China

Huajing Wang

Oricell Therapeutics, Shanghai, China

Xian-Yang Li

Oricell Therapeutics, Shanghai, China

Xiaowen He

Oricell Therapeutics, Shanghai, China

Xiaopei Li

2Oricell Therapeutics, Shanghai, China

Qi Deng

2Oricell Therapeutics, Shanghai, China